Day One Biopharmaceuticals Confirms Merger Completion, Delisting from Nasdaq

summarizeSummary

Day One Biopharmaceuticals announced the successful completion of Servier's tender offer and subsequent merger, resulting in the company becoming a wholly-owned subsidiary and its shares ceasing to trade on Nasdaq.

check_boxKey Events

• Tender Offer Completed

  Servier's tender offer for Day One Biopharmaceuticals successfully expired on April 22, 2026, with 85.34% of shares tendered.

• Merger Finalized

  The acquisition by Servier was completed on April 23, 2026, making Day One Biopharmaceuticals a wholly-owned subsidiary.

• Delisting Initiated

  Day One's common stock ceased trading on Nasdaq prior to market open on April 23, 2026, and the company has requested delisting and deregistration.

• Cash Consideration

  Remaining shareholders will receive the Offer Price of $21.50 per share for their converted shares.

auto_awesomeAnalysis

This filing confirms the definitive end of Day One Biopharmaceuticals as a publicly traded entity. The successful completion of the tender offer and merger means shareholders who did not tender their shares will receive the $21.50 per share offer price. The initiation of delisting from Nasdaq and deregistration with the SEC marks the final step in the company's acquisition by Servier. Investors should be aware that their shares will be converted to cash at the offer price, and the stock will no longer be available for trading.